Creutzig U - Search Results

1

The role of intensive AML-specific therapy in treatment of children with RAEB and RAEB-t.

Creutzig U, Bender-Götze C, Ritter J, Zimmermann M, Stollmann-Gibbels B, Körholz D, Niemeyer C. Creutzig U, et al. Leukemia. 1998 May;12(5):652-9. doi: 10.1038/sj.leu.2400987. Leukemia. 1998. PMID: 9593261

2

[Comparison of chemotherapy alone with allogeneic bone marrow transplantation in first full remission in children with acute myeloid leukemia in the AML-BFM-83 and AML-BFM-87 studies--matched pair analysis].

Creutzig U, Bender-Götze C, Klingebiel T, Ebell W, Friedrich W, Stollmann-Gibbels B, Schmidt H, Suttorp M, Gratwohl A, Heyen P, et al. Creutzig U, et al. Klin Padiatr. 1992 Jul-Aug;204(4):246-52. doi: 10.1055/s-2007-1025355. Klin Padiatr. 1992. PMID: 1518260 Clinical Trial. German.

3

Treatment results of three consecutive German childhood AML trials: BFM-78, -83, and -87. AML-BFM-Group.

Ritter J, Creutzig U, Schellong G. Ritter J, et al. Among authors: creutzig u. Leukemia. 1992;6 Suppl 2:59-62. Leukemia. 1992. PMID: 1578943 Clinical Trial.

4

Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87.

Creutzig U, Harbott J, Sperling C, Ritter J, Zimmermann M, Löffler H, Riehm H, Schellong G, Ludwig WD. Creutzig U, et al. Blood. 1995 Oct 15;86(8):3097-108. Blood. 1995. PMID: 7579404 Free article. Clinical Trial.

5

Myelodysplasia and acute myelogenous leukemia in Down's syndrome. A report of 40 children of the AML-BFM Study Group.

Creutzig U, Ritter J, Vormoor J, Ludwig WD, Niemeyer C, Reinisch I, Stollmann-Gibbels B, Zimmermann M, Harbott J. Creutzig U, et al. Leukemia. 1996 Nov;10(11):1677-86. Leukemia. 1996. PMID: 8892666

6

[Prognosis of children with acute myelocytic leukemia after first relapse].

Creutzig U, Ritter J, Boos J, Zimmermann M, Bender-Götze C, Stahnke K. Creutzig U, et al. Klin Padiatr. 1998 Jul-Aug;210(4):207-11. doi: 10.1055/s-2008-1043880. Klin Padiatr. 1998. PMID: 9743954 German.

7

Duration of first remission predicts remission rates and long-term survival in children with relapsed acute myelogenous leukemia.

Stahnke K, Boos J, Bender-Götze C, Ritter J, Zimmermann M, Creutzig U. Stahnke K, et al. Among authors: creutzig u. Leukemia. 1998 Oct;12(10):1534-8. doi: 10.1038/sj.leu.2401141. Leukemia. 1998. PMID: 9766496

8

Definition of a standard-risk group in children with AML.

Creutzig U, Zimmermann M, Ritter J, Henze G, Graf N, Löffler H, Schellong G. Creutzig U, et al. Br J Haematol. 1999 Mar;104(3):630-9. doi: 10.1046/j.1365-2141.1999.01304.x. Br J Haematol. 1999. PMID: 10086807 Free article.

9

[Prognosis, treatment completion, and complications in nonresponders in the study AML-BFM87].

Kallage V, Müller JE, Zimmermann M, Beck JD, Ritter J, Creutzig U. Kallage V, et al. Among authors: creutzig u. Klin Padiatr. 1999 Jul-Aug;211(4):250-9. doi: 10.1055/s-2008-1043797. Klin Padiatr. 1999. PMID: 10472559 Clinical Trial. German.

10

3 x 14 mg/m2 idarubicin during induction: results of a pilot study in children with AML.

Creutzig U, Körholz D, Niemeyer CM, Kabisch K, Graf N, Reiter A, Scheel-Walter H, Bender-Götze C, Behnisch W, Hermann J, Mann G, Ritter J, Zimmermann M. Creutzig U, et al. Leukemia. 2000 Feb;14(2):340-2. doi: 10.1038/sj.leu.2401670. Leukemia. 2000. PMID: 10673757 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

252 results

Search Page

Filters